Amarin Gets Patents, AstraZeneca Works With Ironwood: Healthcare Business Update

Shares of Amarin Corporation (NASDAQ:AMRN) move up considerably on the news that the USPTO has issued two patents covering the use of its VascepaTM capsules for treating Hypertriglyceridemia. The move forms a part of the firm’s attempt to protect the commercial potential of the drug through the year 2030, and it intends to list both patents in the FDA’s Orange Book.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

AstraZeneca Group (NYSE:AZN) is collaborating with Ironwood Pharmaceuticals (NASDAQ:IRWD) in the co-development and co-commercialization of the latter’s linaclotide in China. The drug is the first and sole guanylate cyclase-C agonist to win FDA approval. Through the terms, AstraZeneca will make an upfront payment of $25 million to Ironwood and will also share in the net profits and losses. Further, the latter will be eligible for $125 million in additional sales-related milestone payments.

Cytori Therapeutics (NASDAQ:CYTX) reports that an investigator-sponsored and funded clinical evaluation of its cell therapy as a potential treatment for scleroderma, has gotten the greenlight to start in France by the National Agency for the Safety of Medicines and Health Products.

Don’t Miss: Eli Lilly: Should Investors be Concerned About This Lackluster Pipeline?